Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07407582 · ClinicalTrials.gov registry record · Phase 1
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
A Phase 1 study, sponsored by University of Arizona.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT07407582 is a Phase 1 study that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 25 participants.
The verdict
NCT07407582, a Phase 1 study, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing hearing loss has been well established in children and is approved for use in the pediatric and young adult population. However, information in adult patients is limited. As most cisplatin is administered in the adult population, this investigation would be of benefit.
Interventions
- DRUG Pedmark® STS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07407582
The ClinicalTrials.gov registry entry for NCT07407582 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pedmark® STS is the first listed.
NCT07407582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07407582 about?
NCT07407582 is a clinical study titled "Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)". The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing hearing loss has been well established in children and is app...
What is the current status of trial NCT07407582?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2026-05-18. Estimated completion is 2028-04-30.
What interventions are being tested in trial NCT07407582?
The interventions under investigation include: Pedmark® STS (DRUG).
Who is sponsoring clinical trial NCT07407582?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.